Clinical trials: Tenosynovial Giant Cell Tumor
Synovial Diseases, Pigmented Villonodular Synovitis
Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease
Through the high-throughput feature extraction of magnetic resonance images, the deep learning prediction model of joint synovial lesions is constructed used for the diagnosis, differential diagnosis and curative effect…
- Conditions
- Synovial Diseases, Pigmented Villonodular Synovitis, Gout, Rheumatoid Arthritis
- Trial name
- NCT04952896
- Testing
- Synovitis diagnosis
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Peking University Third Hospital
Giant Cell Tumors
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with…
- Trial name
- TOP (NCT02948088)
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 183 people
- Sponsor
- Daiichi Sankyo
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT).
- Conditions
- Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
- Trial name
- NCT05804045
- Testing
- Pimicotinib(ABSK021)
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 94 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
AMB-051-01 is a multicenter study with an adaptive design that will enroll subjects with Tenosynovial Giant Cell Tumor (TGCT) of the knee for 12 weeks of multiple-dose, open-label treatment with intra-articular AMB-05X.
- Trial name
- NCT04731675
- Testing
- AMB-05X
- Where
- 6 sites in United States, Netherlands and 2 more
- Volunteers
- 11 people
- Sponsor
- AmMax Bio, Inc.
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS).
- Conditions
- Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
- Trial name
- NCT01207492
- Testing
- nilotinib
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Andrew J. Wagner, MD, PhD
Synovitis Villonodular
Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis
Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by the proliferation of synovial tissue, leading to significant pain and joint destruction.
- Trial name
- SYVIPRO (NCT07503821)
- Testing
- synovial biopsy
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Solid Tumors, Tenosynovial Giant Cell Tumor
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory…
- Conditions
- Solid Tumors, Tenosynovial Giant Cell Tumor, Synovitis, Pigmented Villonodular
- Trial name
- NCT02673736
- Testing
- PLX73086
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Plexxikon
Drug Interaction Potential
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.
- Trial name
- NCT03291288
- Testing
- Tolbutamide, Midazolam, Pexidartinib
- Where
- 11 sites in United States, Netherlands and 2 more
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Pigmented Villonodular Synovitis, TGCT
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor
- Conditions
- Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
- Trial name
- NCT05349643
- Testing
- AMB-05X
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- AmMax Bio, Inc.
Tenosynovial Giant Cell Tumor
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
- Trial name
- NCT07499362
- Testing
- Pimicotinib
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
- Conditions
- Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
- Trial name
- NCT01804530
- Testing
- PLX7486 TsOH
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Plexxikon
Tenosynovial Giant Cell Tumor
A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT
To evaluate the efficacy, safety, and pharmacokinetics of DCC-3014 in subjects with Tenosynovial Giant Cell Tumor
- Trial name
- NCT07832747
- Testing
- DCC-3014
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Tenosynovial Giant Cell Tumor
Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
This study evaluates the diagnostic accuracy of Indocyanine Green (ICG) fluorescence imaging in visualizing Tenosynovial Giant Cell Tumor (TGCT) lesions during surgery.
- Trial name
- ICG-TGCT (NCT07315841)
- Testing
- Indocyanine Green
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
TGCT
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse…
- Trial name
- TANGENT (NCT05417789)
- Testing
- Emactuzumab
- Where
- 33 sites in United States, Belgium and 10 more
- Volunteers
- 128 people
- Sponsor
- SynOx Therapeutics Limited
Tenosynovial Giant Cell Tumor
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic…
- Trial name
- NCT04703322
- Testing
- Pexidartinib
- Where
- 6 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the…
- Conditions
- Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse
- Trial name
- MOTION (NCT05059262)
- Testing
- Vimseltinib
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 123 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor
MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.
- Trial name
- MOVE (NCT07075471)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
- Trial name
- PLX3397 (NCT04526704)
- Testing
- Pexidartinib
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.
- Trial name
- FPA008-002 (NCT02471716)
- Testing
- FPA008
- Where
- 12 sites in United States, France and 4 more
- Volunteers
- 66 people
- Sponsor
- Five Prime Therapeutics, Inc.
Neoplasms, Tenosynovial Giant Cell Tumor
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021.
- Trial name
- NCT04192344
- Testing
- ABSK021
- Where
- 17 sites in United States, China
- Volunteers
- 276 people
- Sponsor
- Abbisko Therapeutics Co, Ltd